Correlation Between Medigen Vaccine and Ruentex Development

Can any of the company-specific risk be diversified away by investing in both Medigen Vaccine and Ruentex Development at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Vaccine and Ruentex Development into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Medigen Vaccine Biologics and Ruentex Development Co, you can compare the effects of market volatilities on Medigen Vaccine and Ruentex Development and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Vaccine with a short position of Ruentex Development. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Vaccine and Ruentex Development.

Diversification Opportunities for Medigen Vaccine and Ruentex Development

0.52

Correlation Coefficient

Medigen Vaccine  Ruentex Development

Very weak diversification

The 3 months correlation between Medigen and Ruentex is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Vaccine Biologics and Ruentex Development Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ruentex Development and Medigen Vaccine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Vaccine Biologics are associated (or correlated) with Ruentex Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ruentex Development has no effect on the direction of Medigen Vaccine i.e., Medigen Vaccine and Ruentex Development go up and down completely randomly.

Pair Corralation between Medigen Vaccine and Ruentex Development

Assuming the 90 days trading horizon Medigen Vaccine Biologics is expected to under-perform the Ruentex Development. In addition to that, Medigen Vaccine is 1.32 times more volatile than Ruentex Development Co. It trades about -0.26 of its total potential returns per unit of risk. Ruentex Development Co is currently generating about -0.03 per unit of volatility. If you would invest  4,695  in Ruentex Development Co on September 13, 2024 and sell it today you would lose (120.00) from holding Ruentex Development Co or give up 2.56% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Medigen Vaccine Biologics  vs.  Ruentex Development Co

Medigen Vaccine Biologics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Vaccine Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Ruentex Development

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ruentex Development Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Ruentex Development is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Medigen Vaccine and Ruentex Development

The main advantage of trading using opposite Medigen Vaccine and Ruentex Development positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Vaccine position performs unexpectedly, Ruentex Development can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ruentex Development will offset losses from the drop in Ruentex Development's long position.

The idea behind Medigen Vaccine Biologics and Ruentex Development Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.